Overall, SMCI has a consensus rating of “Hold,” slipping from the “Moderate Buy” rating it held three months ago. Out of 11 analysts, one rates the AI stock as a “Strong Buy,” one advises a “Moderate ...
2, 2024 — Researchers have found a potential new way to improve the treatment of multiple sclerosis (MS) using a novel combined therapy. The results build on two harmonized Phase I clinical ...
2, 2024 — Researchers have found a potential new way to improve the treatment of multiple sclerosis (MS) using a novel combined therapy. The results build on two harmonized Phase I clinical ...